{"content":"<li class=\"n-box-item date-title\" data-end=\"1496894399\" data-start=\"1496808000\" data-txt=\"Monday, December 23, 2019\">Wednesday, June  7, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3272264\" data-ts=\"1496875443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272264-mylan-defends-chairman-to-iss-ahead-of-investor-vote\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan defends chairman to ISS ahead of investor vote</a></h4><ul>     <li>Mylan (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) released a <a href=\"https://seekingalpha.com/filing/3584824\" target=\"_blank\">letter</a> today that defended Chairman Robert Coury's role to ISS as the proxy firm prepares to advise shareholders on how they should vote on the re-election of Coury and other directors, according to Reuters.</li>     <li>MYL met with ISS on Monday and discussed the role of Coury in growing the company, according to the letter, and defended the Chairman's $97M compensation as well as the company's dealings with Teva (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>), saying it never received a takeover offer from the Israeli drugmaker in 2015.</li>     <li>MYL's letter may have aimed in part at <a href=\"http://www.reuters.com/article/us-mylan-board-idUSKBN18Y21V\" target=\"_blank\">convincing ISS to let it see a copy of the advisory report</a> before publication, which ISS says it will not do.</li>     <li>Big New York and California pension funds are urging shareholders to vote on June 22 against Coury and five other directors, citing Coury's pay package, the handling of the Teva offer and investigations into how much it charged the government and consumers for its EpiPen emergency allergy treatment.</li><li>MYL rose 2% in today's regular trading but <font color='red'>-3.3%</font>&nbsp;AH.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272264\" data-linked=\"Mylan defends chairman to ISS ahead of investor vote\" data-tweet=\"$MYL $MYL $TEVA - Mylan defends chairman to ISS ahead of investor vote https://seekingalpha.com/news/3272264-mylan-defends-chairman-to-iss-ahead-of-investor-vote?source=tweet\" data-url=\"https://seekingalpha.com/news/3272264-mylan-defends-chairman-to-iss-ahead-of-investor-vote\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272260\" data-ts=\"1496873335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRWI\" target=\"_blank\">DRWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272260-dragonwave-continues-rise-up-25_7-on-good-listing-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DragonWave continues rise, up 25.7% on good listing news</a></h4><ul>   <li>Volatile trading is starting to become the rule for DragonWave (NASDAQ:<a href='https://seekingalpha.com/symbol/DRWI' title='DragonWave Inc.'>DRWI</a>) -- <font color='green'>up 71.9%</font> during market hours today, following its <a href=\"https://seekingalpha.com/news/3271986-dragonwave-jumps-50-percent-smartsky-contract-win\" target=\"_blank\">latest news of a contract win</a> (of undisclosed financial terms), and now <font color='green'>up another 25.7%</font> postmarket as it's received a <a href=\"https://seekingalpha.com/pr/16856066-dragonwave-inc-receives-positive-nasdaq-listing-determination\" target=\"_blank\">positive determination on its Nasdaq listing</a>.</li>    <li>The company says Nasdaq has granted its request for continued listing contingent on hitting interim milestones and complying with the $2.5M stockholders' equity requirement by Oct. 17.</li>    <li>Volume during market hours was just short of 15.6M shares, vs. a regular average of 174,859.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272260\" data-linked=\"DragonWave continues rise, up 25.7% on good listing news\" data-tweet=\"$DRWI - DragonWave continues rise, up 25.7% on good listing news https://seekingalpha.com/news/3272260-dragonwave-continues-rise-up-25_7-on-good-listing-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3272260-dragonwave-continues-rise-up-25_7-on-good-listing-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272255\" data-ts=\"1496871453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272255-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+10.8%</font>. <a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color='green'>+7.4%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+3.6%</font>. ETE <font color='green'>+2.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/GEF' title='Greif, Inc.'>GEF</a> <font color='red'>-9.2%</font>. <a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/MSGN' title='MSG Networks'>MSGN</a> <font color='red'>-2.9%</font>. SCSS <font color='red'>-2.5%</font>. <a href='https://seekingalpha.com/symbol/HOPE' title='Hope Bancorp, Inc.'>HOPE</a> <font color='red'>-2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272255\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$VSTM $OKTA $WLB - After Hours Gainers / Losers https://seekingalpha.com/news/3272255-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3272255-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272246\" data-ts=\"1496869119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OKTA\" target=\"_blank\">OKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272246-okta-beats-estimates-and-guidance-in-first-earnings-report-shares-up-4_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Okta beats estimates, and guidance, in first earnings report; shares up 4.8%</a></h4><ul><li>Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>) Q1 report EPS and revenue estimates. Q1 was Okta's first earnings report since the IPO. Subscription revenue was $48.4M, up 75.4% on the prior year&rsquo;s quarter. Other key metrics include $9.7M in cash used in operations, negative $13.3M FCF, and $224.2M in cash and equivalents.</li><li>Q2 guidance includes revenue of $55M-$56M with the loss per share at $0.26-$0.25.</li><li>FY18 guidance puts revenue at $233M-$236M, compared to $226.99 consensus, with a loss per share between $1.15 and $1.11, which is better than the consensus estimate of $1.19 loss.</li><li><a href=\"https://seekingalpha.com/pr/16855950-okta-announces-record-first-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press release</a></li><li>Okta shares are&nbsp;<font color='green'>up 4.82%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272246\" data-linked=\"Okta beats estimates, and guidance, in first earnings report; shares up 4.8%\" data-tweet=\"$OKTA - Okta beats estimates, and guidance, in first earnings report; shares up 4.8% https://seekingalpha.com/news/3272246-okta-beats-estimates-and-guidance-in-first-earnings-report-shares-up-4_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3272246-okta-beats-estimates-and-guidance-in-first-earnings-report-shares-up-4_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272233\" data-ts=\"1496867573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONVO\" target=\"_blank\">ONVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272233-organovo-fiscal-q4-revenue-800k-see-100-growth-next-year-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Organovo fiscal Q4 revenue $800K, could see 100% growth next year; shares down 2% after hours</a></h4><ul><li>Organovo (NASDAQ:<a href='https://seekingalpha.com/symbol/ONVO' title='Organovo Holdings, Inc.'>ONVO</a>) <a href=\"https://seekingalpha.com/pr/16855947-organovo-announces-fiscal-fourth-quarter-full-year-2017-results-company-issues-full-year\" target=\"_blank\">fiscal Q4 results</a> ($M): Revenue: 0.8 (+48.2%); Net Loss: (10.7) (-27.4%); Loss/Share: (0.10) (-11.1%); CF Ops (full year): (29.2) (+0.7%); Quick Assets: 62.8 (+1.1%).</li><li>Revenue for the year was $4.2M (+185%).</li><li><strong>Fiscal 2018 guidance</strong>: Revenue: $6.0M - 8.5M; non-GAAP EBITDA: ($29.0M - 31.0M).</li><li>Key objective for next 12 months: advance therapeutic liver tissue through preclinical testing to finalize design and conduct animal disease model studies.</li><li>Shares are off&nbsp;<font color='red'>2%</font>&nbsp;after hours in average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272233\" data-linked=\"Organovo fiscal Q4 revenue $800K, could see 100% growth next year; shares down 2% after hours\" data-tweet=\"$ONVO - Organovo fiscal Q4 revenue $800K, could see 100% growth next year; shares down 2% after hours https://seekingalpha.com/news/3272233-organovo-fiscal-q4-revenue-800k-see-100-growth-next-year-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3272233-organovo-fiscal-q4-revenue-800k-see-100-growth-next-year-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272230\" data-ts=\"1496866969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAP\" target=\"_blank\">TAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272230-molson-coors-lower-after-analyst-day-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Molson Coors lower after analyst day talk</a></h4><ul>     <li>Molson Coors (NYSE:<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a>)&nbsp;<font color='red'>fell 6.50%</font>&nbsp;today, with most of the decline arriving after the company posted a financial update during its analyst day presentation.</li><li>By assuming full control of MillerCoors, the brewer expects to generate $550M of cost savings by 2019.</li>     <li>Management sees underlying EBITDA margins increasing an average of 30bps to 60 bps per year for the next to three to four years.</li><li>A global priorioty is for free cash flow in 2017 to fall within 10% of $1.2B. Another top goal of Molson is to keep its investment grade rating.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272230\" data-linked=\"Molson Coors lower after analyst day talk\" data-tweet=\"$TAP - Molson Coors lower after analyst day talk https://seekingalpha.com/news/3272230-molson-coors-lower-after-analyst-day-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3272230-molson-coors-lower-after-analyst-day-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272229\" data-ts=\"1496866960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSL\" target=\"_blank\">MSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272229-midsouth-bancorp-raising-capital-shares-down-2_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MidSouth Bancorp raising capital; shares down 2.3%</a></h4><ul><li>The lender<a href=\"https://seekingalpha.com/pr/16855942-midsouth-bancorp-inc-announces-public-offering-common-stock\" target=\"_blank\"> is selling $50M</a> of common stock. Subject to regulatory approval, $32M of the proceeds will be used to redeem preferred stock issued to the U.S. Treasury thanks to its participation in the Small Business Lending Fund.</li><li><a href='https://seekingalpha.com/symbol/MSL' title='MidSouth Bancorp, Inc.'>MSL</a>&nbsp;<font color='red'>-2.3%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3272229\" data-linked=\"MidSouth Bancorp raising capital; shares down 2.3%\" data-tweet=\"$MSL - MidSouth Bancorp raising capital; shares down 2.3% https://seekingalpha.com/news/3272229-midsouth-bancorp-raising-capital-shares-down-2_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3272229-midsouth-bancorp-raising-capital-shares-down-2_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272224\" data-ts=\"1496866582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272224-tailored-brands-beats-0_08-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailored Brands beats by $0.08, misses on revenue</a></h4><ul><li>Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>): Q1 EPS of $0.27 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $782.9M (-5.5% Y/Y) <font color='red'>misses by $10.38M</font>.</li><li>Shares <font color='green'>+2.94%</font>.</li><li><a href='https://seekingalpha.com/pr/16855988-tailored-brands-inc-reports-fiscal-2017-first-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3272224\" data-linked=\"Tailored Brands beats by $0.08, misses on revenue\" data-tweet=\"$TLRD - Tailored Brands beats by $0.08, misses on revenue https://seekingalpha.com/news/3272224-tailored-brands-beats-0_08-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3272224-tailored-brands-beats-0_08-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272223\" data-ts=\"1496866562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGNX\" target=\"_blank\">RGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272223-regenxbio-out-licenses-nav-aav9-vector-to-avexis-for-two-neurologic-disorders-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">REGENXBIO out-licenses NAV AAV9 vector to AveXis for two neurologic disorders; shares ahead 1% after hours</a></h4><ul><li>REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>) extends a <a href=\"https://seekingalpha.com/pr/16855926-regenxbio-avexis-announce-new-exclusive-worldwide-licenses-treatment-two-rare-neurological\" target=\"_blank\">global exclusive license </a>to AveXis (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a>) to develop and commercialize gene therapies using RGNX's NAV AAV9 vector to treat Rett Syndrome and a form of amyotrophic lateral sclerosis &#40;ALS&#41; caused by mutations in a gene called SOD1.</li><li>Under the terms of the agreement, REGENXBIO will receive an undisclosed upfront payment, ongoing fees, milestones and royalties on net sales. Specific financial terms are not disclosed.</li><li>Rett Syndrome, caused by a mutation in a gene called MECP2, is an inherited disorder characterized by slowed growth, coordination and communication skills.</li><li>Inherited ALS represents up to 10% of ALS cases. About one in five of inherited ALS cases are caused by mutations in SOD1.</li><li>RGNX is up&nbsp;<font color='green'>1%</font>&nbsp;after hours on light volume. AVXS is up a fraction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272223\" data-linked=\"REGENXBIO out-licenses NAV AAV9 vector to AveXis for two neurologic disorders; shares ahead 1% after hours\" data-tweet=\"$RGNX $RGNX $AVXS - REGENXBIO out-licenses NAV AAV9 vector to AveXis for two neurologic disorders; shares ahead 1% after hours https://seekingalpha.com/news/3272223-regenxbio-out-licenses-nav-aav9-vector-to-avexis-for-two-neurologic-disorders-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3272223-regenxbio-out-licenses-nav-aav9-vector-to-avexis-for-two-neurologic-disorders-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272218\" data-ts=\"1496866449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272218-verint-systems-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint Systems beats by $0.11, beats on revenue</a></h4><ul><li>Verint Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a>): Q1 EPS of $0.49 <font color='green'>beats by $0.11</font>.</li><li>Revenue of $265.74M (+8.3% Y/Y) <font color='green'>beats by $6.04M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16855965-verint-reports-first-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3272218\" data-linked=\"Verint Systems beats by $0.11, beats on revenue\" data-tweet=\"$VRNT - Verint Systems beats by $0.11, beats on revenue https://seekingalpha.com/news/3272218-verint-systems-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3272218-verint-systems-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272215\" data-ts=\"1496866149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKCC\" target=\"_blank\">BKCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272215-blackrock-capitalminus-2_2-on-convertible-note-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackRock Capital -2.2% on convertible note offering</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16855928-blackrock-capital-investment-corporation-announces-public-offering-convertible-notes-due-2022\" target=\"_blank\">company is offering</a> $125M in principal amount of 5-year senior unsecured convertible notes. The underwriters have an option to buy another $18.75M of the paper.</li><li><a href='https://seekingalpha.com/symbol/BKCC' title='BlackRock Capital Investment Corporation'>BKCC</a>&nbsp;<font color='red'>-2.2%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3272215\" data-linked=\"BlackRock Capital -2.2% on convertible note offering\" data-tweet=\"$BKCC - BlackRock Capital -2.2% on convertible note offering https://seekingalpha.com/news/3272215-blackrock-capitalminus-2_2-on-convertible-note-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3272215-blackrock-capitalminus-2_2-on-convertible-note-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272203\" data-ts=\"1496864706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272203-u-s-steelplus-3-on-standpoints-midday-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Steel +3% on Standpoint&#39;s midday upgrade</a></h4><ul>     <li>U.S. Steel (<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+2.8%</font>) is <a href=\"http://www.barrons.com/articles/u-s-steel-thanks-for-the-upgrade-1496863224\" target=\"_blank\">upgraded to Buy</a> from Hold with a $28 price target at Standpoint Research, providing the stock with a second wind after early gains following a <a href=\"https://seekingalpha.com/news/3272149-u-s-steel-falling-apart-j-p-morgan-says-suggesting-time-buy\" target=\"_blank\">positive note</a> from J.P. Morgan failed to stick.</li>     <li>Standpoint analyst Ronnie Moas calls X \"a high-beta, cyclical name,\" with his fear of a recession and/or a market correction offset by the expectation that a significant infrastructure spending bill will be passed.</li>     <li>Moas believes X is undervalued, trading at 10x estimates for next year, and acknowledges \"some debt\" but also $1.2B in cash vs. a $3.6B market cap.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272203\" data-linked=\"U.S. Steel +3% on Standpoint&#39;s midday upgrade\" data-tweet=\"$X - U.S. Steel +3% on Standpoint&#39;s midday upgrade https://seekingalpha.com/news/3272203-u-s-steelplus-3-on-standpoints-midday-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3272203-u-s-steelplus-3-on-standpoints-midday-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272194\" data-ts=\"1496862487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272194-hertz-lower-again-financial-pressure-mounts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hertz lower again as financial pressure mounts</a></h4><ul> <li>Hertz Global (<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='red'>-6.2%</font>) trades lower after S&amp;P Global Ratings cuts its rating on a series of second-lien secured notes to BB- from BB.</li> <li>Bloomberg reports that some of the company's debt is trading lower (higher yield), in particular a 5.5% note due in 2024 is now yielding over 10%.</li> <li>Shares of Hertz are down 57% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3272194\" data-linked=\"Hertz lower again as financial pressure mounts\" data-tweet=\"$HTZ - Hertz lower again as financial pressure mounts https://seekingalpha.com/news/3272194-hertz-lower-again-financial-pressure-mounts?source=tweet\" data-url=\"https://seekingalpha.com/news/3272194-hertz-lower-again-financial-pressure-mounts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272193\" data-ts=\"1496862445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANAB\" target=\"_blank\">ANAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272193-sell-off-in-anaptysbio-continues-shares-down-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-off in AnaptysBio continues; shares down 19%</a></h4><ul><li>Thinly traded micro cap AnaptysBio (<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a> <font color='red'>-18.5%</font>) slumps on more than double normal volume, albeit on turnover of only 136K shares. The stock has lost ~35% of its value since last week.</li><li>Tomorrow, CEO Hamza Suria will deliver a corporate <a href=\"https://seekingalpha.com/pr/16849050-anaptysbio-participate-upcoming-investor-conferences\" target=\"_blank\">presentation </a>at the Jefferies Global Healthcare Conference in New York.</li><li>The relatively young public biotech develops therapeutic antibodies to treat inflammatory diseases. Its lead product candidate is Phase 2-stage ANB020 for the potential treatment of atopic dermatitis, severe peanut allergy and eosinophilic asthma.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3235521-anaptysbio-deck-ipo\" target=\"_blank\">AnaptysBio on deck for IPO</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3272193\" data-linked=\"Sell-off in AnaptysBio continues; shares down 19%\" data-tweet=\"$ANAB - Sell-off in AnaptysBio continues; shares down 19% https://seekingalpha.com/news/3272193-sell-off-in-anaptysbio-continues-shares-down-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3272193-sell-off-in-anaptysbio-continues-shares-down-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272191\" data-ts=\"1496862028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272191-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/OCC' title='Optical Cable Corporation'>OCC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/TSRI' title='TSR, Inc.'>TSRI</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CAMT' title='Camtek Ltd.'>CAMT</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272191\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$MYSZ $OCC $HQY - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3272191-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3272191-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272183\" data-ts=\"1496861207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERS\" target=\"_blank\">CERS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272183-pas-shortage-less-disruptive-expected-cerus-up-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PAS shortage less disruptive than expected, Cerus up 13%</a></h4><ul><li>Cerus (<a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a> <font color='green'>+13.2%</font>) is up on more than double normal volume in response to its <a href=\"https://seekingalpha.com/pr/16855068-cerus-provides-update-u-s-platelet-additive-solution-pas-supply\" target=\"_blank\">announcement</a> that the previously announced shortage of Fresenius Kabi platelet additive solution &#40;PAS&#41; will be less disruptive than anticipated.</li><li>The key development was the FDA's agreement to review Fresenius' regulatory submission under special guidelines (CBE-30) that allow the distribution of the product during the review period. The CBE-30 (Changes Being Effected in 30 Days) was necessary to address changes in raw materials used by the manufacturer of the PAS container.</li><li>The PAS is a key component for Cerus customers who produce INTERCEPT platelets on a particular apheresis platform.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269267-cerus-lowers-revenue-guidance-due-pas-shortage-shares-5-percent-premarket\" target=\"_blank\">Cerus lowers revenue guidance due to PAS shortage; shares down 5% premarket</a> (May 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3272183\" data-linked=\"PAS shortage less disruptive than expected, Cerus up 13%\" data-tweet=\"$CERS - PAS shortage less disruptive than expected, Cerus up 13% https://seekingalpha.com/news/3272183-pas-shortage-less-disruptive-expected-cerus-up-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3272183-pas-shortage-less-disruptive-expected-cerus-up-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272182\" data-ts=\"1496860692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272182-august-hearings-set-on-potential-dakota-access-pipeline-fines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">August hearings set on potential Dakota Access pipeline fines</a></h4><ul>     <li>North Dakota regulators have <a href=\"https://finance.yahoo.com/news/hearings-scheduled-potential-dakota-access-pipeline-fines-170918903.html\" target=\"_blank\">scheduled August hearings</a> on offenses alleged against Dakota Access pipeline developer Energy Transfer Partners (ETP <font color='red'>-2%</font>).</li>     <li>The North Dakota Public Service Commission is investigating whether ETP removed too many trees and shrubs while laying pipe in the state and improperly reported the discovery of Native American artifacts along the route.</li>     <li>ETP, which could face fines of as much as $400K if found to have violated state rules, says it did not do anything wrong.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272182\" data-linked=\"August hearings set on potential Dakota Access pipeline fines\" data-tweet=\"$ET - August hearings set on potential Dakota Access pipeline fines https://seekingalpha.com/news/3272182-august-hearings-set-on-potential-dakota-access-pipeline-fines?source=tweet\" data-url=\"https://seekingalpha.com/news/3272182-august-hearings-set-on-potential-dakota-access-pipeline-fines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272176\" data-ts=\"1496858466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272176-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/TANH' title='Tantech Holdings'>TANH</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272176\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$GBR $NDRO-OLD $SNES - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3272176-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3272176-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272169\" data-ts=\"1496854940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272169-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HGSH' title='China HGS Real Estate, Inc.'>HGSH</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a> <font color='green'>+7%</font>.DDR <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEL' title='American Equity Investment Life Holding Company'>AEL</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272169\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$HGSH $MBI $SITC - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3272169-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3272169-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272168\" data-ts=\"1496854651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVI\" target=\"_blank\">CVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272168-senators-seek-epa-documents-on-icahns-biofuels-dealings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senators seek EPA documents on Icahn&#39;s biofuels dealings</a></h4><ul>     <li>Five Democratic senators ask the EPA to <a href=\"http://www.reuters.com/article/usa-biofuels-icahn-idUSL1N1J320F\" target=\"_blank\">hand over documents</a> relating to the role of Carl Icahn in shaping biofuels policy at the agency.</li>     <li>The senators say they are concerned that Icahn's dual role as a high-powered investor and an adviser to Pres. Trump on regulation could lead to conflicts of interest; Icahn owns a majority stake in oil refiner CVR Energy (<a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='red'>-2.1%</font>), which is affected by U.S. policies requiring refiners to blend biofuels into their gasoline and diesel.</li>     <li>The CFTC <a href=\"https://seekingalpha.com/news/3271698-reuters-cftc-probing-icahn-biofuels-credits\" target=\"_blank\">earlier this week</a> said it would not investigate Icahn because RINs - the biofuels blending credits that many U.S. refiners are required to purchase under current regulations - are not traded on futures markets.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272168\" data-linked=\"Senators seek EPA documents on Icahn&#39;s biofuels dealings\" data-tweet=\"$CVI - Senators seek EPA documents on Icahn&#39;s biofuels dealings https://seekingalpha.com/news/3272168-senators-seek-epa-documents-on-icahns-biofuels-dealings?source=tweet\" data-url=\"https://seekingalpha.com/news/3272168-senators-seek-epa-documents-on-icahns-biofuels-dealings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272165\" data-ts=\"1496854603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WINS\" target=\"_blank\">WINS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272165-wins-finance-nearly-triples-on-session-company-unaware-of-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wins Finance nearly triples on session; company unaware of news</a></h4><ul><li>Beijing-based Wins Finance (<a href='https://seekingalpha.com/symbol/WINS' title='Wins Finance Holdings Inc.'>WINS</a> <font color='green'>+147.9%</font>) tells <a href=\"https://pbs.twimg.com/media/DBqbJJIUIAE86Q0.jpg\" target=\"_blank\">Bloomberg it doesn't know</a> what's going on, and is unaware of any news that might be causing the move.</li><li>Earlier this year, Wins <a href=\"https://seekingalpha.com/news/3254480-40-bagger-wins-finance-slips-16-percent-analysts-look\" target=\"_blank\">had been up as much as</a> 40x from its late 2015 debut on the Nasdaq. Prior to today's move, it had given back about all of that gain.</li><li><strong>Update:</strong> Shares have been halted from trade. They were&nbsp;<font color='green'>up 153%</font>&nbsp;at the halt.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272165\" data-linked=\"Wins Finance nearly triples on session; company unaware of news\" data-tweet=\"$WINS - Wins Finance nearly triples on session; company unaware of news https://seekingalpha.com/news/3272165-wins-finance-nearly-triples-on-session-company-unaware-of-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3272165-wins-finance-nearly-triples-on-session-company-unaware-of-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272164\" data-ts=\"1496854349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272164-dave-busters-rallies-to-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s rallies to all-time high</a></h4><ul> <li>Shares of Dave &amp; Buster's (<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='green'>+2.9%</font>) glided to an all-time high of $73.18 after the company topped revenue expectations in a quarter in which margins also expanded.</li> <li>BMO Capital Markets says that there could be more gains to come as it backs an Outperform rating and boosts its price target to $77.</li> <li>\"Not only has PLAY exceeded consensus EBITDA every quarter since its IPO, but we also believe there are incremental margin opportunities throughout the income statement,\" reads a <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/06/9576787/dave-busters-impresses-where-it-matters\" target=\"_blank\">note</a> from the firm.</li> <li>Jefferies is also impressed, reiterating a Buy rating on PLAY, and lifting its price target to $80. The investment firm thinks that even the raised guidance from D&amp;B is conservative.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271943-dave-and-busters-beats-0_06-beats-revenue\" target=\"_blank\">Dave &amp; Buster's beats by $0.06, beats on revenue</a> (June 6)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271957-dave-and-busters-lower-earnings\" target=\"_blank\">Dave &amp; Buster's lower after earnings</a> (June 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272164\" data-linked=\"Dave &amp; Buster&#39;s rallies to all-time high\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s rallies to all-time high https://seekingalpha.com/news/3272164-dave-busters-rallies-to-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3272164-dave-busters-rallies-to-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272163\" data-ts=\"1496853854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRCH\" target=\"_blank\">TRCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272163-torchlight-energy-set-to-start-permian-drilling-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Torchlight Energy set to start Permian drilling program</a></h4><ul>     <li>Torchlight Energy (<a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='red'>-8.1%</font>) says it will <a href=\"https://seekingalpha.com/pr/16854946-torchlight-commence-first-horizontal-well-permian-midland-basin-acreage\" target=\"_blank\">begin drilling its first horizontal well</a> on its  Permian Basin assets this weekend.</li><li>TRCH expects the well to encounter multiple pay zones and is planned to have a lateral length of 8K ft. targeting the Wolfcamp A formation.</li><li>TRCH says well completion procedures, including a multi-stage fracturing, are scheduled for late July or early August.</li><li>Shares are sharply lower despite the news, as energy stocks are broadly and sharply lower following today's bearish oil inventory data.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272163\" data-linked=\"Torchlight Energy set to start Permian drilling program\" data-tweet=\"$TRCH - Torchlight Energy set to start Permian drilling program https://seekingalpha.com/news/3272163-torchlight-energy-set-to-start-permian-drilling-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3272163-torchlight-energy-set-to-start-permian-drilling-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272161\" data-ts=\"1496853654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBCI\" target=\"_blank\">GBCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272161-glacier-bancorp-higher-after-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glacier Bancorp higher after acquisition</a></h4><ul><li>Montana-based Glacier Bancorp (<a href='https://seekingalpha.com/symbol/GBCI' title='Glacier Bancorp, Inc.'>GBCI</a> <font color='green'>+1.6%</font>) is adding to its Colorado holdings, <a href=\"https://seekingalpha.com/pr/16854617-glacier-bancorp-inc-announces-acquisition-columbine-capital-corp-buena-vista-colorado\" target=\"_blank\">last night announcing an agreement</a> to purchase Buena Vista, CO-based Collegiate Peaks Bank. It would be Glacier's 19th deal since 2000, 8th in the last five years, and 4th in Colorado.</li><li>Glacier will be paying $15.7M in cash and 1.7M shares of its common stock for Collegiate - based on yesterday's close, a deal value of $73.9M.</li><li>As of March 31, Collegiate had total assets of $469M, gross loans of $331M, and deposits of $401M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272161\" data-linked=\"Glacier Bancorp higher after acquisition\" data-tweet=\"$GBCI - Glacier Bancorp higher after acquisition https://seekingalpha.com/news/3272161-glacier-bancorp-higher-after-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/3272161-glacier-bancorp-higher-after-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272160\" data-ts=\"1496853531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272160-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CVNA' title='Carvana Co.'>CVNA</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CAMT' title='Camtek Ltd.'>CAMT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272160\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MYSZ $GBR $CVNA - Midday Gainers / Losers https://seekingalpha.com/news/3272160-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3272160-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272159\" data-ts=\"1496853063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFX\" target=\"_blank\">NFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272159-oil-producers-sink-following-bearish-eia-storage-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil producers sink following bearish EIA storage data</a></h4><ul>     <li>Energy stocks populate today's biggest decliners in the wake of <a href=\"https://seekingalpha.com/news/3272134-oil-tumbles-2017-low-inventory-build-energy-sector-drops-1-percent\" target=\"_blank\">bearish data on U.S. crude inventories</a>, which has sent crude oil plummeting: WTI <font color='red'>-4.3%</font> at $46.10/bbl, Brent <font color='red'>-3.4%</font> at $48.39/bbl.</li>     <li>Independent E&amp;P companies seen as particularly sensitive to the price of oil are taking the heaviest hit: <a href='https://seekingalpha.com/symbol/NFX' title='Newfield Exploration Co.'>NFX</a> <font color='red'>-6.3%</font>, <a href='https://seekingalpha.com/symbol/DVN' title='Devon Energy Corporation'>DVN</a> <font color='red'>-5.6%</font>, <a href='https://seekingalpha.com/symbol/MRO' title='Marathon Oil Corporation'>MRO</a> <font color='red'>-5.5%</font>, <a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='red'>-5.1%</font>, <a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a> <font color='red'>-3.9%</font>, <a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color='red'>-2.3%</font>, <a href='https://seekingalpha.com/symbol/OXY' title='Occidental Petroleum Corporation'>OXY</a> <font color='red'>-1%</font>.</li>     <li>Among the global supermajors: <a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a> <font color='red'>-0.7%</font>, <a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a> <font color='red'>-1.7%</font>, <a href='https://seekingalpha.com/symbol/TOT' title='TOTAL S.A.'>TOT</a> -<font color='red'>1.9%</font>, <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> <font color='red'>-2.2%</font>.</li><li>Also: <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='red'>-9.1%</font>, <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-8.9%</font>, <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='red'>-8.4%</font>, <a href='https://seekingalpha.com/symbol/SM' title='SM Energy Company'>SM</a> <font color='red'>-8.4%</font>, <a href='https://seekingalpha.com/symbol/WLL' title='Whiting Petroleum Corporation'>WLL</a> <font color='red'>-8.1%</font>, <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='red'>-7%</font>, <a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='red'>-7%</font>, <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='red'>-7%</font>, <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-6.7%</font>, <a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a> <font color='red'>-6.5%</font>, <a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='red'>-6.4%</font>, <a href='https://seekingalpha.com/symbol/PDS' title='Precision Drilling Corporation'>PDS</a> <font color='red'>-6.1%</font>, <a href='https://seekingalpha.com/symbol/SEMG' title='SemGroup Corporation'>SEMG</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272159\" data-linked=\"Oil producers sink following bearish EIA storage data\" data-tweet=\"$NFX $NFX $DVN - Oil producers sink following bearish EIA storage data https://seekingalpha.com/news/3272159-oil-producers-sink-following-bearish-eia-storage-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3272159-oil-producers-sink-following-bearish-eia-storage-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>99&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272153\" data-ts=\"1496851241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272153-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MYE' title='Myers Industries, Inc.'>MYE</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272153\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$HOME $GIII $MYE - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3272153-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3272153-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272154\" data-ts=\"1496851127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDS\" target=\"_blank\">HDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272154-hd-supply-downgraded-baird-after-weak-guidance-in-show-me-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HD Supply downgraded at Baird after weak guidance in &quot;show me&quot; quarter</a></h4><ul><li>HD&nbsp;Supply (<a href='https://seekingalpha.com/symbol/HDS' title='HD Supply'>HDS</a> <font color='red'>-5.7%</font>) extends <a href=\"https://seekingalpha.com/news/3271854-hd-supply-minus-18-percent-announcements\" target=\"_blank\">yesterday's 18% plunge</a> that followed its Q1 earnings miss, weak Q2 guidance and the $2.5B sale of its Waterworks business unit.</li><li>HDS is hit today with at least three <a href=\"https://www.streetinsider.com/Analyst+Comments/Baird+Downgrades+HD+Supply+Holdings+%28HDS%29+to+Neutral/12986914.html\" target=\"_blank\">analyst downgrades</a>; Baird cuts shares to Neutral from Outperform with a $37 price target, down from $47, citing disappointing guidance in a \"show me\" quarter, with accelerated investment spending driving further  uncertainty.</li><li>Baird says catalysts have burned off, competitive and margin fears are  rising, and valuation does not appear inexpensive; while downside may be limited, the firm sees little near-term upside potential and expects in-line performance from current levels.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272154\" data-linked=\"HD Supply downgraded at Baird after weak guidance in &quot;show me&quot; quarter\" data-tweet=\"$HDS - HD Supply downgraded at Baird after weak guidance in &quot;show me&quot; quarter https://seekingalpha.com/news/3272154-hd-supply-downgraded-baird-after-weak-guidance-in-show-me-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3272154-hd-supply-downgraded-baird-after-weak-guidance-in-show-me-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272148\" data-ts=\"1496849814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNN\" target=\"_blank\">RNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272148-rexahn-pharma-announces-direct-equity-sale-to-institutional-investors-shares-slip-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rexahn Pharma announces direct equity sale to institutional investors; shares slip 15%</a></h4><ul><li>Nano cap Rexahn Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='red'>-14.7%</font>) is down on a 50% spike in volume in response to its <a href=\"https://seekingalpha.com/pr/16855162-rexahn-announces-10-million-registered-direct-offering\" target=\"_blank\">direct placement</a> of equity with institutional investors. The company has agreed to sell 3.03M units at $3.30/unit yielding gross proceeds of $10M.</li><li>Each unit consists of one share of common stock and one five-year warrant to purchase 1/2 of a share of common at $4.00. Closing date is June 12.</li><li>Net proceeds will fund clinical trials, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272148\" data-linked=\"Rexahn Pharma announces direct equity sale to institutional investors; shares slip 15%\" data-tweet=\"$RNN $REXN - Rexahn Pharma announces direct equity sale to institutional investors; shares slip 15% https://seekingalpha.com/news/3272148-rexahn-pharma-announces-direct-equity-sale-to-institutional-investors-shares-slip-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3272148-rexahn-pharma-announces-direct-equity-sale-to-institutional-investors-shares-slip-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272146\" data-ts=\"1496849350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACGL\" target=\"_blank\">ACGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272146-arch-capital-groupminus-2_6-after-profit-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arch Capital Group -2.6% after profit warning</a></h4><ul><li>At issue is the company's property facultative reinsurance operations. Arch (<a href='https://seekingalpha.com/symbol/ACGL' title='Arch Capital Group Ltd.'>ACGL</a> <font color='red'>-2.6%</font>) expects a hit (relative to normal profitability) <a href=\"https://seekingalpha.com/filing/3584504\" target=\"_blank\">of $38M in Q2</a>, related to losses incurred on a small number of contracts across multiple underwriting years.</li><li>Arch notes the operation has been consistently and significantly profitable since its 2007 inception.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272146\" data-linked=\"Arch Capital Group -2.6% after profit warning\" data-tweet=\"$ACGL - Arch Capital Group -2.6% after profit warning https://seekingalpha.com/news/3272146-arch-capital-groupminus-2_6-after-profit-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3272146-arch-capital-groupminus-2_6-after-profit-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272138\" data-ts=\"1496848542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSTI\" target=\"_blank\">SSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272138-strong-debut-for-shotspotter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong debut for Shotspotter</a></h4><ul> <li>Shotspotter (NASDAQ:<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a>) opens trading at $12.20 to fly past the $11 mark where shares were priced.</li> <li>In early trading, Shotspotter went as high as $13.35 before falling back to $12.56 at last check.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3272097-buzzworthy-shotspotter-prices-ipo\" target=\"_blank\">Buzzworthy Shotspotter prices IPO</a> (June 7)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271324-ipo-watch-shotspotter-making-noise\" target=\"_blank\">IPO watch: Shotspotter making some noise</a> (June 2)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3272138\" data-linked=\"Strong debut for Shotspotter\" data-tweet=\"$SSTI - Strong debut for Shotspotter https://seekingalpha.com/news/3272138-strong-debut-for-shotspotter?source=tweet\" data-url=\"https://seekingalpha.com/news/3272138-strong-debut-for-shotspotter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272137\" data-ts=\"1496848340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTH\" target=\"_blank\">DLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272137-52-week-low-for-duluth-holdings-after-weak-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">52-week low for Duluth Holdings after weak profit</a></h4><ul> <li>Duluth Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a>) is&nbsp;<font color='red'>down 17%</font>&nbsp;after missing estimates with its <a href=\"https://seekingalpha.com/pr/16854449-duluth-holdings-inc-announces-first-quarter-fiscal-2017-financial-results\" target=\"_blank\">Q1 report</a>.</li> <li>The company reported a narrower quarterly profit than last year, despite the 22% jump in revenue. A higher advertising/marketing spend was partially behind the bottom line reversal for Duluth. Advertising/marketing costs as a percentage of sales increased 320 bps to 25.2% during the quarter.</li> <li>Looking ahead, Duluth still is in an expansion mode, with plans to open 12 retail stores and one outlet store this fiscal year.</li> <li>Shares of Duluth hit a 52-week low of $16.83 earlier today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272137\" data-linked=\"52-week low for Duluth Holdings after weak profit\" data-tweet=\"$DLTH - 52-week low for Duluth Holdings after weak profit https://seekingalpha.com/news/3272137-52-week-low-for-duluth-holdings-after-weak-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3272137-52-week-low-for-duluth-holdings-after-weak-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272136\" data-ts=\"1496848308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WB\" target=\"_blank\">WB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272136-nine-masts-investor-urges-buying-weibo-through-parent-sina\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nine Masts investor urges buying Weibo through parent Sina</a></h4><ul>   <li>Investor James Tu likes Chinese microblogging site Weibo (<a href=\"http://seekingalpha.com/symbol/WB\" target=\"_blank\">WB</a> <font color='green'>+4.3%</font>), but with the stock relatively expensive, recommends a different way of getting in: <a href=\"http://www.barrons.com/articles/sohn-hong-kong-how-to-own-weibo-without-buying-the-stock-1496818669\" target=\"_blank\">through its parent Sina</a> (<a href=\"http://seekingalpha.com/symbol/SINA\" target=\"_blank\">SINA</a> <font color='green'>+3.8%</font>).</li>    <li>Presenting at the Sohn Hong Kong conference, Nine Masts co-founder Tu notes Sina's stake in Weibo (which has <font color='green'>rallied 166%</font> over the past year) is <a href=\"https://seekingalpha.com/news/3270219-sina-plus-2_2-percent-distributes-part-weibo-stake-holders\" target=\"_blank\">set to decline</a> and that the implied price/share for Weibo in Sina's share price is $35.55 (vs. the current $78.74).</li>    <li>The best risk/reward approach may be convertible bonds, though, Tu says: \"Buy Sina convertible bonds, which give you a balanced exposure to Sina, which has a chairman who is doing everything in his power to close the value discount in Sina by either spinning off Weibo shares or buying large amounts of Sina shares.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272136\" data-linked=\"Nine Masts investor urges buying Weibo through parent Sina\" data-tweet=\"$WB $WB $SINA - Nine Masts investor urges buying Weibo through parent Sina https://seekingalpha.com/news/3272136-nine-masts-investor-urges-buying-weibo-through-parent-sina?source=tweet\" data-url=\"https://seekingalpha.com/news/3272136-nine-masts-investor-urges-buying-weibo-through-parent-sina\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272134\" data-ts=\"1496847716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272134-oil-tumbles-to-2017-low-after-inventory-build-energy-sector-drops-over-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil tumbles to 2017 low after inventory build; energy sector drops over 1%</a></h4><ul><li>Black gold was already under pressure today, and <a href=\"https://seekingalpha.com/news/3272121-crude-futures-decline-post-inventory-data\" target=\"_blank\">then the EIA reported</a> a surprise 3.3M barrel increase in inventories. Crude's now<font color='red'> down 4.5%</font>&nbsp;to $46 per barrel - roughly matching its 2017 low set one month ago. <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>&nbsp;<font color='red'>-4.25%</font></li><li>That in turn is dragging down the energy sector (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color='red'>-1.4%</font>), (<a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a> <font color='red'>-3%</font>), (<a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a> <font color='red'>-2.9%</font>).</li><li>The Dow, S&amp;P 500, and Nasdaq remain modestly higher on the session.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Guggenheim S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='PowerShares Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3272134\" data-linked=\"Oil tumbles to 2017 low after inventory build; energy sector drops over 1%\" data-tweet=\"$USO $XLE $XOP - Oil tumbles to 2017 low after inventory build; energy sector drops over 1% https://seekingalpha.com/news/3272134-oil-tumbles-to-2017-low-after-inventory-build-energy-sector-drops-over-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3272134-oil-tumbles-to-2017-low-after-inventory-build-energy-sector-drops-over-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272108\" data-ts=\"1496847643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272108-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ALOG' title='Analogic Corporation'>ALOG</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272108\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$SVRA $CALA $CERS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3272108-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3272108-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272130\" data-ts=\"1496847086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNPR\" target=\"_blank\">JNPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272130-juniper-networks-taps-brocade-exec-to-lead-emea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juniper Networks taps Brocade exec to lead EMEA</a></h4><ul>   <li>Juniper Networks (<a href=\"http://seekingalpha.com/symbol/JNPR\" target=\"_blank\">JNPR</a> <font color='red'>-2.4%</font>) has <a href=\"https://seekingalpha.com/pr/16854691-juniper-networks-announces-new-leadership-emea-business\" target=\"_blank\">set leadership</a> for its Europe, Middle East and Africa business by putting Brocade's Marcus Jewell in charge.</li>    <li>Jewell was named senior VP and general manager for the EMEA business, taking responsibility for sales operations including go-to-market and channel strategies.</li>    <li>He ran the EMEA business at Brocade along with leading global software sales.</li>    <li>Jewell will be based in Amsterdam, where Juniper has its regional executive briefing center along with technical support operations and facilities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272130\" data-linked=\"Juniper Networks taps Brocade exec to lead EMEA\" data-tweet=\"$JNPR - Juniper Networks taps Brocade exec to lead EMEA https://seekingalpha.com/news/3272130-juniper-networks-taps-brocade-exec-to-lead-emea?source=tweet\" data-url=\"https://seekingalpha.com/news/3272130-juniper-networks-taps-brocade-exec-to-lead-emea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272128\" data-ts=\"1496846786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVRA\" target=\"_blank\">SVRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272128-savara-up-16-ahead-of-friday-corporate-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Savara up 16% ahead of Friday corporate update</a></h4><ul><li>Thinly traded nano cap Savara (<a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a> <font color='green'>+16.4%</font>) perks up on average volume in early trading. CEO Rob Neville is scheduled to deliver a corporate <a href=\"https://seekingalpha.com/pr/16851968-savara-present-jefferies-2017-global-healthcare-conference-june-9th\" target=\"_blank\">presentation </a>on Friday at the Jefferies 2017 Global Healthcare Conference.</li><li>Shares had lost ~60% of their value in May before rebounding.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272128\" data-linked=\"Savara up 16% ahead of Friday corporate update\" data-tweet=\"$SVRA - Savara up 16% ahead of Friday corporate update https://seekingalpha.com/news/3272128-savara-up-16-ahead-of-friday-corporate-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3272128-savara-up-16-ahead-of-friday-corporate-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272129\" data-ts=\"1496846777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLF\" target=\"_blank\">SLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272129-sun-life-leads-insurers-higher-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sun Life leads insurers higher after upgrade</a></h4><ul><li>via Bloomberg</li><li>RBC's Darko Mihelic downgraded Sun Life (NYSE:<a href='https://seekingalpha.com/symbol/SLF' title='Sun Life Financial, Inc.'>SLF</a>) earlier this year, but with the stock&nbsp;<font color='red'>down more than 12%</font>&nbsp;since, the valuation is looking good alongside signs of improving operations.</li><li>Mihelic notes strong asset growth in the investment management business in the first two months of Q2.</li><li>He upgrades to Outperform from Sector Perform. Shares in New York are&nbsp;<font color='green'>higher by 2.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272129\" data-linked=\"Sun Life leads insurers higher after upgrade\" data-tweet=\"$SLF - Sun Life leads insurers higher after upgrade https://seekingalpha.com/news/3272129-sun-life-leads-insurers-higher-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3272129-sun-life-leads-insurers-higher-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272126\" data-ts=\"1496846534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLS\" target=\"_blank\">SPLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272126-cerberus-said-to-bid-over-6b-for-staples\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerberus said to bid over $6B for Staples</a></h4><ul> <li>Sources tell StreetInsider that Cerberus Capital Management increased its <a href=\"https://www.streetinsider.com/Hot+M+and+A/Cerberus+Said+to+Increase+Offer+to+Acquire+Staples+%28SPLS%29+-+Source/12988730.html\" target=\"_blank\">offer</a> for Staples (<a href='https://seekingalpha.com/symbol/SPLS' title='Staples, Inc.'>SPLS</a> <font color='green'>+0.1%</font>) to more than $6B. The bid is said to be less than a $7B valuation.</li> <li>Sycamore Partners is also still in the hunt for the retail chain.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3272126\" data-linked=\"Cerberus said to bid over $6B for Staples\" data-tweet=\"$SPLS - Cerberus said to bid over $6B for Staples https://seekingalpha.com/news/3272126-cerberus-said-to-bid-over-6b-for-staples?source=tweet\" data-url=\"https://seekingalpha.com/news/3272126-cerberus-said-to-bid-over-6b-for-staples\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272125\" data-ts=\"1496846461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QHC\" target=\"_blank\">QHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272125-quorum-jettisons-two-pennsylvania-hospitals-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quorum jettisons two Pennsylvania hospitals; shares down 7%</a></h4><ul><li>Quorum Health (<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-6.6%</font>) slumps on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16855054-quorum-health-corporation-announces-definitive-agreement-divest-two-hospitals-pennsylvania\" target=\"_blank\">announcement </a>that it has inked an agreement with UPMC Susquehanna to sell two hospitals in the state, 70-bed Sunbury Community and 47-bed Lock Haven, for an undisclosed sum. The transaction should close by the end of next quarter.</li><li>The company has yet to break out of a long-term downtrend that began in January. Shares have lost almost 65% of their value this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272125\" data-linked=\"Quorum jettisons two Pennsylvania hospitals; shares down 7%\" data-tweet=\"$QHC - Quorum jettisons two Pennsylvania hospitals; shares down 7% https://seekingalpha.com/news/3272125-quorum-jettisons-two-pennsylvania-hospitals-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3272125-quorum-jettisons-two-pennsylvania-hospitals-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272123\" data-ts=\"1496846015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272123-sangamos-hemophilia-candidate-orphan-drug-in-europe-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo&#39;s hemophilia A candidate an Orphan Drug in Europe; shares ahead 2%</a></h4><ul><li>The European Medicines Agency <a href=\"https://seekingalpha.com/pr/16854873-sangamo-therapeutics-pfizer-announce-sbminus-525-investigational-hemophilia-gene-therapy\" target=\"_blank\">designates </a>Sangamo Therapeutics' (<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='green'>+2.1%</font>) gene therapy candidate SB-525 an Orphan Drug for the treatment of hemophilia A.</li><li>Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.</li><li>The company is developing gene therapies to treat the bleeding disorder with collaboration partner Pfizer under a May 2017 agreement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3266158-sangamo-teams-pfizer-develop-gene-therapies-treat-hemophilia-shares-ahead-41-percent-hours\" target=\"_blank\">Sangamo teams up with Pfizer to develop gene therapies to treat hemophilia A; shares ahead 41% after hours</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3272123\" data-linked=\"Sangamo&#39;s hemophilia A candidate an Orphan Drug in Europe; shares ahead 2%\" data-tweet=\"$SGMO - Sangamo&#39;s hemophilia A candidate an Orphan Drug in Europe; shares ahead 2% https://seekingalpha.com/news/3272123-sangamos-hemophilia-candidate-orphan-drug-in-europe-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3272123-sangamos-hemophilia-candidate-orphan-drug-in-europe-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272121\" data-ts=\"1496845863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272121-crude-futures-decline-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures decline further post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>+3.3M</strong> barrels vs. -3.5M consensus, -6.4M last week.</li>     <li>Gasoline <strong>+3.3M</strong> barrels vs. +0.6M consensus, -2.9M last week.</li>     <li>Distillates <strong>+4.4M </strong>vs. +0.3M consensus, +0.4M last week.</li>     <li>Futures&nbsp;<font color='red'>-1.18%</font>&nbsp;to $47.61.</li>     <li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3272121\" data-linked=\"Crude futures decline further post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures decline further post inventory data https://seekingalpha.com/news/3272121-crude-futures-decline-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3272121-crude-futures-decline-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272116\" data-ts=\"1496844967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HA\" target=\"_blank\">HA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272116-hawaiian-holdingsplus-6-after-crackerjack-traffic-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hawaiian Holdings +6% after crackerjack traffic report</a></h4><ul> <li>Hawaiian Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a>) reports revenue passenger miles increased 8.0% to 1.369B in <a href=\"https://seekingalpha.com/pr/16854591-hawaiian-airlines-reports-may-2017-traffic-statistics-updates-expected-second-quarter-metrics\" target=\"_blank\">May</a>.</li> <li>Capacity was up 5.0% to 1.579B available seat miles.</li> <li>May load factor +240 bps to 86.7%. YTD load factor +270 bps to 84.8%.</li> <li>The company expects Q2 operating revenue per available seat mile to increase 7.5% to 10.5%, a boost in guidance from the prior view for a 5.5% to 8.5% gain.</li> <li>Shares of Hawaiian Holdings are <font color='green'>up 6.34%</font> to hit their highest level since January.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272116\" data-linked=\"Hawaiian Holdings +6% after crackerjack traffic report\" data-tweet=\"$HA - Hawaiian Holdings +6% after crackerjack traffic report https://seekingalpha.com/news/3272116-hawaiian-holdingsplus-6-after-crackerjack-traffic-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3272116-hawaiian-holdingsplus-6-after-crackerjack-traffic-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272114\" data-ts=\"1496844942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272114-mid-stage-data-on-novavaxs-rsv-vaccine-candidate-published-in-leading-journal-shares-ahead-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mid-stage data on Novavax&#39;s RSV vaccine candidate published in leading journal; shares ahead 10%</a></h4><ul><li>Novavax (<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='green'>+9.8%</font>) is up in early trading on the news that Phase 2 results on its RSV F protein recombinant nanoparticle vaccine candidate have just been <a href=\"https://seekingalpha.com/pr/16855021-novavax-rsv-f-vaccine-phase-2-clinical-trial-data-women-child-bearing-age-published-vaccine\" target=\"_blank\">published </a>in the journal <em>Vaccine</em> (it took awhile, top-line data were <a href=\"http://ir.novavax.com/phoenix.zhtml?c=71178&amp;p=irol-newsArticle_pf&amp;ID=1923116\" target=\"_blank\">reported </a>in April 2014).</li><li>Women receiving the vaccine showed ~12-fold increases in anti-F IgG responses, peaking 14 days post-vaccination and sustained for the three-month evaluation period. New RSV infections were reduced 52% compared to placebo.</li><li>A large-scale <a href=\"https://clinicaltrials.gov/ct2/show/NCT02624947?term=novavax&amp;phase=2&amp;rank=1\" target=\"_blank\">Phase 3 study</a> is ongoing. According to ClinicalTrials.gov, the estimated completion date is June 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272114\" data-linked=\"Mid-stage data on Novavax&#39;s RSV vaccine candidate published in leading journal; shares ahead 10%\" data-tweet=\"$NVAX - Mid-stage data on Novavax&#39;s RSV vaccine candidate published in leading journal; shares ahead 10% https://seekingalpha.com/news/3272114-mid-stage-data-on-novavaxs-rsv-vaccine-candidate-published-in-leading-journal-shares-ahead-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3272114-mid-stage-data-on-novavaxs-rsv-vaccine-candidate-published-in-leading-journal-shares-ahead-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272113\" data-ts=\"1496844380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVNA\" target=\"_blank\">CVNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272113-post-earning-rip-for-carvana-and-auto-retail-peers-follow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earning rip for Carvana and auto retail peers follow</a></h4><ul> <li>Carvana (<a href='https://seekingalpha.com/symbol/CVNA' title='Carvana Co.'>CVNA</a> <font color='green'>+15.9%</font>) races higher after posting a Q1 earnings beat and issuing strong guidance.</li> <li>The company expects Q2 revenue of $193M to $203M vs. $184M consensus and full-year revenue of $850M to $910M vs. $854M consensus.</li> <li>\"We continue to see increased consumer adoption of online car buying across our markets, charting a clear path to consistent growth within the $710 billion U.S. used auto market,\" says Carvana CEO Ernie Garcia.</li> <li>The strong report from Carvana isn't necessarily rattling investors in the auto retail sector. Both AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color='green'>+0.9%</font>) and Group 1 Automotive (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color='green'>+1.9%</font>) are ahead of market averages, while Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color='green'>+0.9%</font>) and Sonic Automotive (<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a> <font color='red'>-0.3%</font>) are also holding their own.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271947-carvana-beats-0_01-beats-revenue\" target=\"_blank\">Carvana beats by $0.01, beats on revenue</a> (June 6)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272113\" data-linked=\"Post-earning rip for Carvana and auto retail peers follow\" data-tweet=\"$CVNA $CVNA $AN - Post-earning rip for Carvana and auto retail peers follow https://seekingalpha.com/news/3272113-post-earning-rip-for-carvana-and-auto-retail-peers-follow?source=tweet\" data-url=\"https://seekingalpha.com/news/3272113-post-earning-rip-for-carvana-and-auto-retail-peers-follow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272112\" data-ts=\"1496844337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMCX\" target=\"_blank\">AMCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272112-amc-networksplus-1_9-adds-500m-to-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Networks +1.9% as it adds $500M to buyback</a></h4><ul>   <li>AMC Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/AMCX' title='AMC Networks Inc.'>AMCX</a>) is <font color='green'>up 1.9%</font> early this morning after announcing a <a href=\"https://seekingalpha.com/pr/16854995-amc-networks-inc-announces-500-million-increase-stock-repurchase-program\" target=\"_blank\">$500M boost</a> to its stock repurchase program</li>    <li>The new authorization is in addition to a $500M authorization set March 7, 2016.</li>    <li>The buyback program doesn't have a closing date.</li>    <li>After a May tumble of 8.3%, shares are up just 4.2% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272112\" data-linked=\"AMC Networks +1.9% as it adds $500M to buyback\" data-tweet=\"$AMCX - AMC Networks +1.9% as it adds $500M to buyback https://seekingalpha.com/news/3272112-amc-networksplus-1_9-adds-500m-to-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3272112-amc-networksplus-1_9-adds-500m-to-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272106\" data-ts=\"1496843823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MATN\" target=\"_blank\">MATN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272106-mateons-oxi4503-fast-trackd-for-aml-shares-ahead-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mateon&#39;s OXi4503 Fast Track&#39;d for AML; shares ahead 18%</a></h4><ul><li>Thinly traded nano cap Mateon Therapeutics (<a href='https://seekingalpha.com/symbol/MATN' title='Mateon Therapeutics, Inc.'>OTCQB:MATN</a> <font color='green'>+17.8%</font>) heads north on the <a href=\"https://seekingalpha.com/pr/16854888-mateon-therapeutics-receives-fda-fast-track-designation-oxi4503-patients-acute-myeloid\" target=\"_blank\">news </a>that the FDA has designated Orphan Drug-tagged OXi4503 for Fast Track review for the treatment of acute myeloid leukemia &#40;AML&#41;.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application.</li><li>Phase 2-stage&nbsp;<a href=\"https://www.mateon.com/product-development/taboxi4503/\" target=\"_blank\">OXi4503 </a>(combretastatin A1-diphosphate) is a dual mechanism vascular disrupting agent. It weakens the tumor vasculature which causes tumor cell death and potentially affects the cell shape and attachment of hematopoietic stem cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272106\" data-linked=\"Mateon&#39;s OXi4503 Fast Track&#39;d for AML; shares ahead 18%\" data-tweet=\"$MATN - Mateon&#39;s OXi4503 Fast Track&#39;d for AML; shares ahead 18% https://seekingalpha.com/news/3272106-mateons-oxi4503-fast-trackd-for-aml-shares-ahead-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3272106-mateons-oxi4503-fast-trackd-for-aml-shares-ahead-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272099\" data-ts=\"1496842056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALA\" target=\"_blank\">CALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272099-calitheras-cbminus-839-fast-trackd-for-kidney-cancer-shares-ahead-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calithera&#39;s CB-839 Fast Track&#39;d for kidney cancer; shares ahead 6% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16854777-calithera-biosciences-announces-fda-fast-track-designation-granted-cbminus-839-treatment\" target=\"_blank\">designates </a>Calithera Biosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a>) lead product candidate CB-839 for Fast Track review for the treatment of metastatic renal cell carcinoma, in combination with Novartis' AFINITOR (everolimus), in patients who have received at least two prior lines of therapy.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application.</li><li><a href=\"http://www.calithera.com/programs/cb-839/\" target=\"_blank\">CB-839</a>&nbsp;is an orally administered inhibitor of an enzyme called glutaminase. It is designed to starve tumor cells of a protein called glutamine, a key nutrient. The rationale is that it may enhance the effects of checkpoint inhibitors and may reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and promoting an anti-tumor immune response.</li><li>Shares are up&nbsp;<font color='green'>6%&nbsp;</font>premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272099\" data-linked=\"Calithera&#39;s CB-839 Fast Track&#39;d for kidney cancer; shares ahead 6% premarket\" data-tweet=\"$CALA - Calithera&#39;s CB-839 Fast Track&#39;d for kidney cancer; shares ahead 6% premarket https://seekingalpha.com/news/3272099-calitheras-cbminus-839-fast-trackd-for-kidney-cancer-shares-ahead-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3272099-calitheras-cbminus-839-fast-trackd-for-kidney-cancer-shares-ahead-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272096\" data-ts=\"1496841791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBDC\" target=\"_blank\">GBDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272096-golub-capital-down-2-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golub Capital down 2% after share sale</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16855163-golub-capital-bdc-inc-prices-public-offering-1750-000-shares-common-stock\" target=\"_blank\">company reports pricing</a> its 1.75M share secondary offering, but doesn't detail the price or the amount raised. The underwriter &#40;UBS&#41; retains an option to buy another 262.5K shares the offering price.</li><li><a href='https://seekingalpha.com/symbol/GBDC' title='Golub Capital BDC'>GBDC</a>&nbsp;<font color='red'>-2%</font>&nbsp;premarket to $19.30.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271955-golub-capital-1_2-percent-capital-raise\" target=\"_blank\">Golub Capital down 1.2% on capital raise</a> (June 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3272096\" data-linked=\"Golub Capital down 2% after share sale\" data-tweet=\"$GBDC - Golub Capital down 2% after share sale https://seekingalpha.com/news/3272096-golub-capital-down-2-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3272096-golub-capital-down-2-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272095\" data-ts=\"1496841578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272095-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='red'>-15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16855162-rexahn-announces-10-million-registered-direct-offering\" target=\"_blank\">announcing</a> $10M direct offering.</li><li><a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3272043-shire-bails-gvhd-candidate-g1-aat-iv-u-s-licensor-kamada-8-percent-premarket\" target=\"_blank\">announcement</a> of Shire Plc transferring its IND for Graft-Versus-Host Disease (GvHD) candidate Alpha-1 Antitrypsin (G1-AAT IV) to Kamada&nbsp;Ltd.</li><li><a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3272052-navistar-disclose-pricing-info-dod\" target=\"_blank\">agreeing</a> to disclose pricing info to DOD.</li><li><a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3271953-exact-sciences-inks-deal-underwriters-sell-8_05m-common-shares-shares-slip-5-percent-hours\" target=\"_blank\">signing</a> deal to sell 8.05M common shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272095\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$REXN $KMDA $NAV - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3272095-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3272095-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272094\" data-ts=\"1496841511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272094-fda-accepts-synergys-marketing-application-for-expanded-use-of-trulance-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Synergy&#39;s marketing application for expanded use of Trulance; shares ahead 4% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16855237-synergy-pharmaceuticals-announces-acceptance-supplemental-new-drug-application-snda-trulance\" target=\"_blank\">accepts for review</a> Synergy Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a>) supplemental New Drug Application (sNDA) seeking approval of TRULANCE (plecanatide) for the treatment of irritable bowel syndrome with constipation (IBS-C). The agency's action date &#40;PDUFA&#41; is January 24, 2018.</li><li>The FDA approved <a href=\"http://www.synergypharma.com/research-and-development/trulance\" target=\"_blank\">TRULANCE </a>to treat chronic idiopathic constipation in January.</li><li>Share are up&nbsp;<font color='green'>4%</font>&nbsp;premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272094\" data-linked=\"FDA accepts Synergy&#39;s marketing application for expanded use of Trulance; shares ahead 4% premarket\" data-tweet=\"$SGYP $SGYP-OLD - FDA accepts Synergy&#39;s marketing application for expanded use of Trulance; shares ahead 4% premarket https://seekingalpha.com/news/3272094-fda-accepts-synergys-marketing-application-for-expanded-use-of-trulance-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3272094-fda-accepts-synergys-marketing-application-for-expanded-use-of-trulance-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>171&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272089\" data-ts=\"1496841084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272089-tevas-migraine-candidate-fremanezumab-successful-in-second-late-stage-study-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva&#39;s migraine candidate fremanezumab successful in second late-stage study; shares ahead 1% premarket</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16854936-tevas-fremanezumab-meets-primary-and-secondary-endpoints-across-monthly-quarterly-dosing\" target=\"_blank\">announcement </a>of positive results in a second Phase 3 study, HALO, assessing fremanezumab (TEV-48125) for the prevention of migraine.</li><li>Fremanezumab administered once/month showed superiority to placebo as measured by change from baseline in average migraine days per month, number of days with disability and medication consumed. All endpoints are achieved and were highly statistically significant.</li><li>More detailed results will be submitted for presentation at future medical conferences and for publication. A U.S. marketing application is planned for later this year with approval expected in H2 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3270722-tevas-fremanezumab-successful-late-stage-migraine-study-u-s-marketing-application-expected\" target=\"_blank\">Teva's fremanezumab successful in late-stage migraine study; U.S. marketing application expected this year; shares up 1%</a> (May 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3272089\" data-linked=\"Teva&#39;s migraine candidate fremanezumab successful in second late-stage study; shares ahead 1% premarket\" data-tweet=\"$TEVA - Teva&#39;s migraine candidate fremanezumab successful in second late-stage study; shares ahead 1% premarket https://seekingalpha.com/news/3272089-tevas-migraine-candidate-fremanezumab-successful-in-second-late-stage-study-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3272089-tevas-migraine-candidate-fremanezumab-successful-in-second-late-stage-study-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272081\" data-ts=\"1496839801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272081-abbvies-upadacitinib-successful-in-late-stage-rheumatoid-arthritis-study-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie&#39;s upadacitinib successful in late-stage rheumatoid arthritis study; shares ahead 1% premarket</a></h4><ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) perks up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume after it announced <a href=\"https://seekingalpha.com/pr/16854894-abbvies-upadacitinib-abtminus-494-meets-primary-ranked-secondary-endpoints-phase-3-study\" target=\"_blank\">positive results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02675426?term=select-next&amp;rank=1\" target=\"_blank\">SELECT-NEXT</a>, evaluating JAK1 inhibitor upadacitinib (ABT-494) for the treatment of rheumatoid arthritis patients who failed to respond adequately to DMARDs (disease-modifying antirheumatic drugs).</li><li>Both doses of upadacitinib (15 mg and 30 mg) handily beat placebo in terms of the proportion of patients achieving ACR20 (20% improvement in symptoms), ACR50, ACR70 and clinical remission at week 12. All differences were statistically significant. The proportions of patients who experienced clinical remission, for example, were 31%, 28% and 10%, respectively, in the 15 mg, 30 mg and placebo groups (p&lt;0.001).</li><li>Upadacitinib's safety profile was consistent with Phase 2 studies.</li><li>It is also being investigated for the treatment of psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272081\" data-linked=\"AbbVie&#39;s upadacitinib successful in late-stage rheumatoid arthritis study; shares ahead 1% premarket\" data-tweet=\"$ABBV - AbbVie&#39;s upadacitinib successful in late-stage rheumatoid arthritis study; shares ahead 1% premarket https://seekingalpha.com/news/3272081-abbvies-upadacitinib-successful-in-late-stage-rheumatoid-arthritis-study-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3272081-abbvies-upadacitinib-successful-in-late-stage-rheumatoid-arthritis-study-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272078\" data-ts=\"1496839550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRM\" target=\"_blank\">IRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272078-iron-mountain-down-1_7-deutsche-cuts-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iron Mountain down 1.7% as Deutsche cuts to Sell</a></h4><ul><li>A lack of positive catalysts combined with headwinds like recall integration, leverage, and rising interest rates has Deutsche's Kevin McVeigh downgrading Iron Mountain (NYSE:<a href='https://seekingalpha.com/symbol/IRM' title='Iron Mountain Inc.'>IRM</a>) to Sell from Hold.</li><li>His price target of $30 (down from $41) suggests&nbsp;<font color='red'>14% downside</font>&nbsp;from yesterday's close.</li><li>Source: Bloomberg</li><li>Shares&nbsp;<font color='red'>-1.7%</font>&nbsp;premarket to $34.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272078\" data-linked=\"Iron Mountain down 1.7% as Deutsche cuts to Sell\" data-tweet=\"$IRM - Iron Mountain down 1.7% as Deutsche cuts to Sell https://seekingalpha.com/news/3272078-iron-mountain-down-1_7-deutsche-cuts-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3272078-iron-mountain-down-1_7-deutsche-cuts-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272077\" data-ts=\"1496839530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EONGY\" target=\"_blank\">EONGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272077-german-utilities-anticipate-big-windfall-after-nuclear-tax-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">German utilities anticipate big windfall after nuclear tax ruling</a></h4><ul>     <li>E.ON (<a href='https://seekingalpha.com/symbol/EONGY' title='E.ON SE ADR'>OTCPK:EONGY</a>) and RWE (<a href='https://seekingalpha.com/symbol/RWEOY' title='RWE AG ADR'>OTCPK:RWEOY</a>) are up more than 4% in Frankfurt trading after Germany's highest court effectively <a href=\"http://www.marketwatch.com/story/eon-rwe-shares-rise-after-german-court-ruling-2017-06-07\" target=\"_blank\">rolled back a tax on nuclear energy</a>, saying the fees the government has collected from utility companies are unconstitutional and \"void.\"</li>     <li>The government has collected ~&euro;4.6B ($5.2B)  from the two utilities since the 2011 imposition of the tax.</li>     <li>E.ON says it expects a one-time boost of &euro;3.3B, including interest, from the ruling and confirms its full-year guidance for adjusted profit.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3272077\" data-linked=\"German utilities anticipate big windfall after nuclear tax ruling\" data-tweet=\"$EONGY $EONGY $RWEOY - German utilities anticipate big windfall after nuclear tax ruling https://seekingalpha.com/news/3272077-german-utilities-anticipate-big-windfall-after-nuclear-tax-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3272077-german-utilities-anticipate-big-windfall-after-nuclear-tax-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272058\" data-ts=\"1496837323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272058-chanos-bearish-on-dialysis-companies-on-unsustainability-of-obamacare-covered-patient-mix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chanos bearish on dialysis companies on unsustainability of Obamacare-covered patient mix</a></h4><ul><li>Renal dialysis-related stocks could be under pressure today on the heels of bearish <a href=\"https://www.bloomberg.com/news/videos/2017-06-07/invest-spotlight-jim-chanos-makes-his-calls-video\" target=\"_blank\">comments</a> from noted short seller Jim Chanos at the Bloomberg Invest Summit.</li><li>Mr. Chanos believes dialysis operators like DaVita (NYSE:<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a>) and American Renal Associates (NYSE:<a href='https://seekingalpha.com/symbol/ARA' title='American Renal Associates Holdings'>ARA</a>) will be unable to maintain earnings because their practice of transferring Medicare patients into Obamacare (where the reimbursement is much higher) is unsustainable. The companies have been big contributors to charities that help patients afford the large private insurance co-pays which enables the scheme to work.</li><li>Dialysis-related tickers: (NYSE:<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGAA'>FMS</a>)(NYSE:<a href='https://seekingalpha.com/symbol/BAX' title='Baxter International Inc'>BAX</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3272058\" data-linked=\"Chanos bearish on dialysis companies on unsustainability of Obamacare-covered patient mix\" data-tweet=\"$DVA $DVA $ARA - Chanos bearish on dialysis companies on unsustainability of Obamacare-covered patient mix https://seekingalpha.com/news/3272058-chanos-bearish-on-dialysis-companies-on-unsustainability-of-obamacare-covered-patient-mix?source=tweet\" data-url=\"https://seekingalpha.com/news/3272058-chanos-bearish-on-dialysis-companies-on-unsustainability-of-obamacare-covered-patient-mix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3272043\" data-ts=\"1496835379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3272043-shire-bails-on-gvhd-candidate-g1-aat-iv-in-u-s-licensor-kamada-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire bails on GvHD candidate G1-AAT IV in U.S., licensor Kamada down 8% premarket</a></h4><ul><li>Prompted by slow recruitment in the first part of a Phase 2/3 study and other pipeline priorities, Shire plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) <a href=\"https://seekingalpha.com/pr/16854836-kamada-provides-update-clinical-program-alphaminus-1-antitrypsin-iv-treatment-graft-versus\" target=\"_blank\">transfers its IND</a> for Graft-Versus-Host Disease (GvHD) candidate Alpha-1 Antitrypsin (G1-AAT IV) to Kamada Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a>), who is developing the product in the EU.</li><li>Shire has stopped the U.S. study. Kamada will resume U.S. development in the next few months after standardizing the study design.</li><li>G1-AAT IV has Orphan Drug status in both the U.S. and EU for the indication.</li><li>Kamada and Shire (Baxter at the time) inked an agreement in 2010 for Kamada's IV AAT under which Shire has exclusive rights in the U.S., Canada, Australia and New Zealand. The companies will continue to collaborate on developing AAT IV for prevention of lung transplant rejection.</li><li>Kamada is down&nbsp;<font color='red'>8%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3272043\" data-linked=\"Shire bails on GvHD candidate G1-AAT IV in U.S., licensor Kamada down 8% premarket\" data-tweet=\"$SHPG $SHPG $KMDA - Shire bails on GvHD candidate G1-AAT IV in U.S., licensor Kamada down 8% premarket https://seekingalpha.com/news/3272043-shire-bails-on-gvhd-candidate-g1-aat-iv-in-u-s-licensor-kamada-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3272043-shire-bails-on-gvhd-candidate-g1-aat-iv-in-u-s-licensor-kamada-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}